Drug Profile
RCD 2
Alternative Names: CEL-02; RCD-2Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Celogos
- Class Cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Faecal incontinence
Most Recent Events
- 01 Mar 2007 Phase-II clinical trials in Faecal Incontinence in France (Parenteral)
- 24 Jul 2006 Phase-I clinical trials in Faecal Incontinence in France (Parenteral)